Jenny Dominguez
VP of Investor Relations
Replay available
McKesson Corporation (NYSE: MCK) Q3 2026 earnings conference call, held 2026-02-04. Replay captured from the company's public earnings webcast.

VP of Investor Relations
Chief Executive Officer
Chief Financial Officer
Bank of America Analyst
Jefferies Analyst
J.P. Morgan Analyst
Learing Partners Analyst
Evercore ISI Analyst
TD Cowen Analyst
Morgan Stanley Analyst
UBS Analyst
Nefron Research Analyst
Barclays Analyst
Deutsche Bank Analyst
Please stand by. Welcome to McKesson's third quarter fiscal 2026 earnings conference call. Please be advised that today's conference is being recorded. At this time, I would like to turn the call over to Jenny Dominguez, VP of investor relations. Please go ahead. Thank you, operator. Good afternoon and welcome everyone to McKesson's third quarter fiscal 2026 earnings call. Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitilone, our Chief Financial Officer. Brian will lead off, followed by Britt, and then we'll move to a question and answer session. Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com. into the risk factor sections of our most recent annual and periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements. Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and guidance assumptions. With that, let me turn it over to Brian. Thank you, Jenny. Good afternoon, everyone. Appreciate you joining McKesson's fiscal third quarter earnings call. Today's results, once again, demonstrate the strength and the durability of our business. Revenue and adjusted EPS grew double digits, driven by continued momentum across oncology, biopharma services, and North American distribution. T...